Department of Health Science, Faculty of Health and Human Development, The University of Nagano, Nagano, Japan; Palliative and Supportive Medicine, Graduate School of Medicine, Aichi Medical University, Nagakute, Aichi, Japan; Department of Geriatric Medicine, Hospital, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan.
Palliative and Supportive Medicine, Graduate School of Medicine, Aichi Medical University, Nagakute, Aichi, Japan; Department of Geriatric Medicine, Hospital, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan.
Mech Ageing Dev. 2022 Dec;208:111728. doi: 10.1016/j.mad.2022.111728. Epub 2022 Sep 6.
In 2022, the European Society for Clinical Nutrition and Metabolism (ESPEN) and European Association for the Study of Obesity (EASO) working group proposed uniform diagnostic criteria for sarcopenic obesity. However, no study has adapted these criteria to an Asian population or examined sarcopenic obesity prevalence diagnosed using these criteria or its association with functional outcomes. This retrospective cohort study investigated sarcopenic obesity prevalence diagnosed based on the ESPEN and EASO criteria, and its association with functional outcomes in 1080 older Japanese patients (mean age 79.5 years, 43.5 % male) undergoing rehabilitation. Based on the mentioned criteria, sarcopenic obesity is defined as a BMI ≥ 25 kg/m, increased percent body fat (PBF), reduced skeletal muscle mass (SMM), and low handgrip strength. Sarcopenic obesity prevalence was investigated using various ESPEN- and EASO-proposed definitions of increased PBF and reduced SMM. Functional outcomes were evaluated based on whether patients improved in the minimal clinically important difference (MCID) of the Functional Independence Measure (FIM). The prevalence was 4.3-5.3 %. Sarcopenic obesity was not independently related to FIM MCID achievement. Sarcopenic obesity prevalence-based on the ESPEN and EASO criteria-in older Japanese patients undergoing rehabilitation was low and was not associated with poor functional outcomes.
2022 年，欧洲临床营养与代谢学会（ESPEN）和欧洲肥胖研究协会（EASO）工作组提出了用于诊断肌少症性肥胖的统一标准。然而，尚无研究将这些标准应用于亚洲人群，也未评估使用这些标准诊断的肌少症性肥胖的流行情况及其与功能结局的相关性。本回顾性队列研究纳入了正在接受康复治疗的 1080 名日本老年患者（平均年龄 79.5 岁，43.5%为男性），旨在探讨基于 ESPEN 和 EASO 标准诊断的肌少症性肥胖的流行情况及其与功能结局的相关性。根据上述标准，肌少症性肥胖定义为 BMI≥25kg/m²、体脂百分比（PBF）增加、骨骼肌质量（SMM）减少和握力降低。使用各种 ESPEN 和 EASO 提出的 PBF 增加和 SMM 减少标准来研究肌少症性肥胖的流行情况。根据功能独立性评定量表（FIM）的临床重要差异（MCID），评估功能结局。肌少症性肥胖的患病率为 4.3%-5.3%。肌少症性肥胖与 FIM MCID 达标无关。基于 ESPEN 和 EASO 标准，在接受康复治疗的日本老年患者中，肌少症性肥胖的患病率较低，且与较差的功能结局无关。
